Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.
genomic medicine
germline mutation
hereditary cancer syndromes
neoplasms
pediatrics
precision medicine
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 11 2023
15 11 2023
Historique:
revised:
17
04
2023
received:
29
08
2022
accepted:
15
05
2023
medline:
30
10
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Germline genome sequencing in childhood cancer precision medicine trials may reveal pathogenic or likely pathogenic variants in cancer predisposition genes in more than 10% of children. These findings can have implications for diagnosis, treatment, and the child's and family's future cancer risk. Understanding parents' perspectives of germline genome sequencing is critical to successful clinical implementation. A total of 182 parents of 144 children (<18 years of age) with poor-prognosis cancers enrolled in the Precision Medicine for Children with Cancer trial completed a questionnaire at enrollment and after the return of their child's results, including clinically relevant germline findings (received by 13% of parents). Parents' expectations of germline genome sequencing, return of results preferences, and recall of results received were assessed. Forty-five parents (of 43 children) were interviewed in depth. At trial enrollment, most parents (63%) believed it was at least "somewhat likely" that their child would receive a clinically relevant germline finding. Almost all expressed a preference to receive a broad range of germline genomic findings, including variants of uncertain significance (88%). Some (29%) inaccurately recalled receiving a clinically relevant germline finding. Qualitatively, parents expressed confusion and uncertainty after the return of their child's genome sequencing results by their child's clinician. Many parents of children with poor-prognosis childhood cancer enrolled in a precision medicine trial expect their child may have an underlying cancer predisposition syndrome. They wish to receive a wide scope of information from germline genome sequencing but may feel confused by the reporting of trial results.
Sections du résumé
BACKGROUND
Germline genome sequencing in childhood cancer precision medicine trials may reveal pathogenic or likely pathogenic variants in cancer predisposition genes in more than 10% of children. These findings can have implications for diagnosis, treatment, and the child's and family's future cancer risk. Understanding parents' perspectives of germline genome sequencing is critical to successful clinical implementation.
METHODS
A total of 182 parents of 144 children (<18 years of age) with poor-prognosis cancers enrolled in the Precision Medicine for Children with Cancer trial completed a questionnaire at enrollment and after the return of their child's results, including clinically relevant germline findings (received by 13% of parents). Parents' expectations of germline genome sequencing, return of results preferences, and recall of results received were assessed. Forty-five parents (of 43 children) were interviewed in depth.
RESULTS
At trial enrollment, most parents (63%) believed it was at least "somewhat likely" that their child would receive a clinically relevant germline finding. Almost all expressed a preference to receive a broad range of germline genomic findings, including variants of uncertain significance (88%). Some (29%) inaccurately recalled receiving a clinically relevant germline finding. Qualitatively, parents expressed confusion and uncertainty after the return of their child's genome sequencing results by their child's clinician.
CONCLUSIONS
Many parents of children with poor-prognosis childhood cancer enrolled in a precision medicine trial expect their child may have an underlying cancer predisposition syndrome. They wish to receive a wide scope of information from germline genome sequencing but may feel confused by the reporting of trial results.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3620-3632Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
J Natl Cancer Inst. 2006 Jan 4;98(1):61-8
pubmed: 16391372
Eur J Cancer Care (Engl). 2018 Nov;27(6):e12877
pubmed: 30016002
Cancer Discov. 2021 Dec 1;11(12):3008-3027
pubmed: 34301788
J Health Psychol. 2008 Oct;13(7):895-905
pubmed: 18809640
J Pers Med. 2018 Sep 17;8(3):
pubmed: 30227640
Genome Med. 2014 Sep 17;6(9):69
pubmed: 25317207
J Med Ethics. 2014 Oct;40(10):691-6
pubmed: 24356209
Trends Cancer. 2020 Jan;6(1):31-39
pubmed: 31952779
Clin Cancer Res. 2017 Oct 15;23(20):6101-6112
pubmed: 28733441
JAMA Oncol. 2016 May 01;2(5):616-624
pubmed: 26822237
JAMA Netw Open. 2019 Apr 5;2(4):e192906
pubmed: 31026031
Clin Cancer Res. 2016 Aug 1;22(15):3810-20
pubmed: 26994145
AJOB Empir Bioeth. 2022 Jul-Sep;13(3):152-165
pubmed: 35471132
Cancer. 2019 Jul 15;125(14):2455-2464
pubmed: 30901077
JAMA. 2015 Sep 1;314(9):913-25
pubmed: 26325560
JAMA Oncol. 2021 Dec 01;7(12):1806-1814
pubmed: 34617981
Cancer. 2017 Jun 15;123(12):2352-2359
pubmed: 28192596
JCO Precis Oncol. 2018 Mar 14;2:
pubmed: 32913997
J Pers Med. 2022 Aug 18;12(8):
pubmed: 36013276
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Cancer. 2023 Nov 15;129(22):3620-3632
pubmed: 37382186
JCO Precis Oncol. 2020;4:202-211
pubmed: 32395682
J Community Genet. 2020 Apr;11(2):139-145
pubmed: 31432391
Fam Cancer. 2017 Oct;16(4):605-610
pubmed: 28405782
JCO Precis Oncol. 2019 Dec;3:1-11
pubmed: 35100729
Eur J Cancer. 2016 Sep;65:91-101
pubmed: 27479119
Genet Med. 2015 Jun;17(6):485-92
pubmed: 25297947
Cancer. 2016 Apr 15;122(8):1238-46
pubmed: 26882017
Nat Med. 2020 Nov;26(11):1742-1753
pubmed: 33020650
BMJ Open. 2020 Jun 23;10(6):e034522
pubmed: 32580982
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Public Health Genomics. 2015;18(5):299-308
pubmed: 26352440
Pediatr Blood Cancer. 2016 Nov;63(11):1974-82
pubmed: 27429135
Clin Cancer Res. 2017 Jul 1;23(13):e91-e97
pubmed: 28674117
Genet Med. 2014 Aug;16(8):633-40
pubmed: 24434691
Nat Cancer. 2021 Mar;2:357-365
pubmed: 34308366
Pediatr Blood Cancer. 2015 Aug;62(8):1374-80
pubmed: 25832998
Patient Educ Couns. 2019 Apr;102(4):680-686
pubmed: 30482469
J Pers Med. 2020 Feb 14;10(1):
pubmed: 32075154
J Law Biosci. 2018 Jan 22;4(3):648-657
pubmed: 29868193
Eur J Pediatr. 2018 Jan;177(1):53-60
pubmed: 28929227
Children (Basel). 2021 Mar 27;8(4):
pubmed: 33801725
Cancer Causes Control. 2008 Jun;19(5):469-79
pubmed: 18197461